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Abstract
Introduction: Achieving HIV epidemic control globally will require new strategies to accelerate reductions in HIV incidence
and mortality. Universal test and treat (UTT) was evaluated in four randomized population-based trials (BCPP/Ya Tsie, HPTN
071/PopART, SEARCH, ANRS 12249/TasP) conducted in sub-Saharan Africa (SSA) during expanded antiretroviral treatment
(ART) eligibility by World Health Organization guidelines and the UNAIDS 90-90-90 campaign.
Discussion: These three-year studies were conducted in Botswana, Zambia, Uganda, Kenya and South Africa in settings with
baseline HIV prevalence from 4% to 30%. Key observations across studies were: (1) Universal testing (implemented via a vari-
ety of home and community-based testing approaches) achieved >90% coverage in all studies. (2) When coupled with robust
linkage to HIV care, rapid ART start and patient-centred care, UTT achieved among the highest reported population levels of
viral suppression in SSA. Significant gains in population-level viral suppression were made in regions with both low and high
baseline population viral load; however, viral suppression gains were not uniform across all sub-populations and were lower
among youth. (3) UTT resulted in marked reductions in community HIV incidence when universal testing and robust linkage
were present. However, HIV elimination targets were not reached. In BCPP and HPTN 071, annualized HIV incidence was
approximately 20% to 30% lower in the intervention (which included universal testing) compared to control arms (no universal
testing). In SEARCH (where both arms had universal testing), incidence declined 32% over three years. (4) UTT reduced HIV
associated mortality by 23% in the intervention versus control communities in SEARCH, a study in which mortality was com-
prehensively measured.
Conclusions: These trials provide strong evidence that UTT inclusive of universal testing increases population-level viral sup-
pression and decreases HIV incidence and mortality faster than the status quo in SSA and should be adapted at a sub-country
level as a public health strategy. However, more is needed, including integration of new prevention interventions into UTT, in
order to reach UNAIDS HIV elimination targets.
Keywords: HIV testing; antiretroviral therapy; HIV elimination; HIV care continuum; HIV prevention; HIV care continuum;
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1 | INTRODUCTION
HIV “treatment as prevention” captivated the HIV field over a
decade ago. When antiretroviral therapy (ART) was shown to
be associated with the secondary benefit of HIV transmission
reduction between sexual partners in observational studies,
treatment as prevention emerged as a new and unchartered
strategy [1–3]. In 2009, Granich and colleagues modelled
reductions in HIV incidence, reductions in death, and cost sav-
ings over the long-term under a variety of conditions of HIV
testing and treatment using South Africa epidemiological and
demographic parameters [4]. Their model predicted that annual
population testing coupled with expanded eligibility for ART
would dramatically reduce new HIV infections within ten years
compared to the current country standard. Proponents
applauded this model as a novel and very promising approach
to HIV epidemic control. Critics challenged the relevance of
the model, doubting in particular the feasibility and cost of uni-
versal and repeated HIV testing and overly optimistic assump-
tions about linkage to care and universal treatment uptake and
its effect on HIV transmission [5]. In 2011, Cohen reported a
96% reduction in HIV incidence associated with ART use in an
individual, randomized study of HIV sero-discordant couples
[6]. At that time, the momentum to study population-level
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treatment as prevention grew and four large population-based
randomized trials of universal test and treat (UTT) were
launched in sub-Saharan Africa (SSA). The primary outcomes of
these four trials (BCPP/YaTsie, HPTN 071/PopART, SEARCH
and ANRS 12249/TasP) have now been published [7–10].
One of the main objectives of the Universal Test and Treat
Trial (UT3C) Consortium, comprised of the UTT trial teams,
was to better inform whether and how population-level HIV
testing and treatment could reduce HIV incidence and mortal-
ity, benchmarked to UNAIDS 2020 targets for HIV epidemic
control. A first paper reported on the contexts, research
methodologies, intervention packages, themes explored, evolu-
tion of study designs and interventions related to each of
these UTT trials [11]. This commentary focuses on the implica-
tions of the trial results published thus far for public health
policy.
2 | DISCUSSION
UTT consortium investigators independently conducted four
studies in South Africa, Zambia, Uganda and Kenya in popula-
tions with HIV prevalence among adults ranging from 4% to
30% (Table 1) between 2012 and 2017. Over one million
community members participated in these studies.
2.1 | UTT study designs
These “first generation” UTT trials all randomized communities
and evaluated multiple interventions that integrated HIV test-
ing, prevention and treatment. The studies were conducted in
southern and eastern Africa across a broad range of settings
from rural to urban. Study follow-up was relatively short –
approximately three years in all studies. The studies took
place during a dynamic period of UNAIDS global campaigns and
changes in World Health Organization (WHO) ART guidelines.
In 2014, UNAIDS launched the 90-90-90 campaign, calling for
countries to reach targets of 90% for knowledge of HIV status,
ART start and viral suppression [13]. In 2013, the WHO
expanded ART eligibility to persons with CD4 count <500 cells/
mm3 plus other high-risk groups. Eligibility was subsequently
expanded to all persons living with HIV in 2015, based on two
large, individual randomized studies [14–17]. All UTT control
communities promptly adopted expanded ART eligibility (2013
WHO guidelines); universal ART eligibility (2015 WHO guideli-
nes) was initiated in the control arms in all studies but TasP, as
South Africa guidelines did not change until the very end of the
study. These changes meant that the anticipated differences
between ART uptake in control and intervention arms were
diminished, although arguably, the amended control arm with
broadened ART eligibility was the relevant comparison.
One critical distinction between the study designs impor-
tant for their interpretation was that comprehensive baseline
HIV testing was done only in the intervention arms in BCPP
and HPTN 071 and in both intervention and control arms in
SEARCH and TasP. In the two latter trials, expanded ART eli-
gibility in the control communities thus occurred in the con-
text of extremely high knowledge of HIV status. Thus,
differences between intervention and control arms were
reduced, and were due primarily to differences in linkage, ART
start and care delivery.
2.2 | HIV testing
The goal of the universal testing intervention in the UTT studies
was to ensure that all persons living with HIV knew their HIV
status and were offered ART. UTT aimed to reach persons not
previously HIV-diagnosed as well as those who were previously
diagnosed and had either not started ART or had fallen out of
care. All studies supplemented health system testing with a
comprehensive “out-of-facility” approach to increase access and
reduce stigma for HIV testing. Community mobilization was
foundational, and the four UTT studies deployed a variety of
approaches. Control communities were also engaged and acti-
vated during the randomization process and during endpoint
measurement in the entire population (SEARCH) or nested
cohorts (other studies). The BCPP, HPTN 071, and TasP teams
implemented home testing enhanced with other mobile testing
outreach [7,9,10]. SEARCH conducted multi-disease health fairs
followed by home testing for non-participants [18]. Each study
incorporated demand-generation strategies for men and youth,
and repeated testing at regular intervals.
In all four UTT studies, over 90% of persons living with HIV
were aware of their status by study end, illustrating that
rapidly achieving the UNAIDS “first 90” target is achievable
(Figure 1A). Baseline knowledge of HIV status spanned from
57% (HPTN 071) to 87% (BCPP). Large absolute increases in
the “first 90” were achieved in HPTN 071 and SEARCH.
Increases in the BCPP and TasP studies were smaller but
equally impressive, as in these communities, HIV testing sites
were well established when trials began—and population-level
gains thus required reaching persons less engaged in existing
health services, such as men and youth.
2.3 | Linkage and ART start
Linkage to care and ART delivery were key intervention com-
ponents of the four UTT trials and were particularly important
in light of out-of-facility HIV testing. Trials used a variety of
patient-centred interventions to bridge HIV testing to clinics
with ongoing retention support [7,9,10,12]. In general, health
workers and community advocates facilitated rapid linkage to
care. SEARCH and BCPP offered rapid ART start, with
SEARCH providing same day ART and co-trimoxazole starter
packs. Supportive clinic environments that avoided punitive
measures for missed visits were part of the study intervention
in SEARCH and TasP, with ongoing staff trainings. Text
appointment reminders, tracing of patients with missed visits,
multi-disease service provision and men and youth friendly
services were additional interventions implemented to varying
degrees in the intervention communities of the trials.
Eighty-eight to 97% of persons aware of their HIV diagnosis
in the intervention arms were on ART (UNAIDS “second 90”)
by trial end in three of the four UTT studies (Figure 1B). In
the TasP study, linkage to care remained a challenge, particu-
larly among youth, those with new HIV diagnosis, higher edu-
cation and those living farther away from clinic, reflecting
barriers also reported by others [19,20].
2.4 | Viral suppression
At baseline in all studies, high percentages of persons who
were in care on ART had viral suppression (UNAIDS “third
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90”), (Figure 1C). One of the concerns raised by critics of the
UTT intervention when the studies were initiated was that
persons with high CD4+ cell count who were asymptomatic
would have poor retention and hence poor viral suppression –
resulting in an overall lower “third 90” [21]. This concern was
greatest for those new-to-care versus those who had already
engaged in care. However, this concern was not realized: by
the end of the studies, viral suppression rates for ART-treated
individuals were ≥87% across the studies. In the BCPP trial,
97% of persons in the measurement cohort in the interven-
tion arm had viral suppression at study end, reflecting highly
successful engagement in HIV care [9].
Table 1. UTT trial design and HIV incidence outcomes in sub-Saharan Africa
Trial BCPP/Ya Tsie HPTN 071 (PopART) SEARCH ANRS 12249 (TasP)
Country Botswana South Africa/Zambia Kenya/Uganda South Africa
Prevalence 29% 22% 4% to 19% 30%
Arm C I C I
Arm A
I
Arm B
C I C I
Universal
testing
U U U U U U U
Home,
mobile
Home +
field
(men,
youth)
Home +
field
(men,
youth)
Multi-dz
Fairs/
Home
Multi-dz
Fairs/
Home
Home Home
Testing
frequency
Baseline;
ongoing
targeted
Ongoing
Annual
Ongoing
~Annual
Baseline Annual 6
monthly
6
monthly
Enhanced
linkage
U U U U U
Rapid ART Start U U
(from 2016)
Universal
Treatment
U U U U U U U U
(from
2016)
(from
2016)
(from
2016)
(from
2016)
(from
2016)
Differentiated
ART Delivery
U U Ua
(Zambiac) (Zambiac)
Population viral
suppression
At start 75% 70% 52% 57%b
74%b
+17b
42% 42% 26% 23%
At end 83% 88% 68% 68% 79% 45% 46%
Difference +8 +18 +16 +26 +37 +19 +23
HIV Incidence
Annual Incidence
for 100
person-years
0.92 0.59 1.55 1.24b 0.27 0.25 2.27 2.11
Reduction
(I vs. C)
31% Reduction 20% Reduction Not significant,
32% reduction in
intervention arm
between years 1 &
3
Not significant
Additional details are previously published [11]. C, control; I, Intervention; UTT, Universal test and treat.
aPatient-centered care, including “friendly provider service,” flexible clinic hours, tiered tracking, and provider access via mobile phone [12]; bboth
intervention arms were pooled for HPTN 071 (PopART) for population viral suppression and HIV incidence; coption for ART delivery in community
adherence groups.
Havlir D et al. Journal of the International AIDS Society 2020, 23:e25455
http://onlinelibrary.wiley.com/doi/10.1002/jia2.25455/full | https://doi.org/10.1002/jia2.25455
3
An underlying premise of the UTT studies was that the
intervention package needed to encompass all steps in the
HIV care cascade in order to increase population-level viral
suppression sufficiently to impact HIV transmission and mor-
tality. Population-level viral suppression ranged from 23%
(TasP) to 70% (BCPP) at study start. Population-level suppres-
sion increased in the intervention arms during all of the stud-
ies and at study close, exceeded the UNAIDS 2020 target of
73% in three of the four studies (Figure 2A). Despite a dou-
bling of population-level viral suppression from baseline in
TasP, the UNAIDS target was not achieved due to low linkage
rates [10].
The extraordinary increases in population-level viral sup-
pression were achieved over a very short period of time. Test-
ing and linkage were critical to this success because viral
suppression among those already on ART was high at baseline.
Population-level viral suppression increases were attained
both from baselines of less than 57% (SEARCH and HPTN
071) and above 70% (BCPP). Consistent with other African
cohort studies, viral suppression among youth was lower than
among older adults [22]. Mobile populations in all the trials
had lower rates of viral suppression compared to non-mobile
populations [7–10]. Men had lower viral suppression rates
than women at study start and only slightly lower rates of
Figure 1. Universal test and treat (UTT) intervention arms: baseline
and end-of study knowledge of HIV status among persons living
with HIV; “First 90” (A); Baseline and end-of-study persons on
antiretroviral therapy (ART) among those HIV diagnosed; “Second 90”
(B); Baseline and end of study viral suppression among those on ART:
“Third 90” (C).
Figure 2. Universal test and treat (UTT) intervention arms: baseline
and end of study population-level viral suppression (A); Population-
level viral suppression from country surveys [24,25] and in the inter-
vention arms in the UTT trials (B) [7–10].
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viral suppression than women at study end. Prior cohort stud-
ies report a marked disparity in men’s engagement in HIV
testing and care in Africa due to a wide range of individual,
structural and societal barriers. The UTT approach reached
and quite successfully engaged men [23]. The many factors
that enabled and motivated men to access HIV testing and
care included home testing, multi-disease services and flexible
clinic services.
The population-level viral suppression (74% to 88%) rapidly
achieved in BCPP, HPTN 071 and SEARCH are among the
highest reported in SSA using contemporary data and far
exceed those of developed countries such as the United
States, where population-level viral suppression was recently
reported as 51% [24] (Figure 2B). Some small African coun-
tries who have invested heavily in HIV testing and treatment
have also notably reached the UNAIDS 73% target: Eswatini
73%; Namibia 77% and Rwanda 76% [25].
2.5 | HIV incidence and mortality
In BCPP and HPTN 071 (when the two intervention arms
were combined in a post hoc analysis), annual HIV incidence
was 20% to 31% lower in the intervention versus control
communities after three years (Table 1). The dissonant finding
that HIV incidence in one of the HPTN 071 intervention arms
did not differ significantly from the control is unexplained, but
may be a result of individual community characteristics. The
SEARCH study, which conducted universal testing in both
arms and rapid ART eligibility expansion in control communi-
ties, did not detect a difference in the primary endpoint of
cumulative three-year HIV incidence between intervention
and control arms. Annual HIV incidence in SEARCH did
decrease by 32% between the first and third years of the
study in the intervention arm; further, cumulative HIV inci-
dence was approximately 27% lower than a modelled control
arm that did not have universal baseline testing [26]. No dif-
ference in cumulative HIV incidence was detected between
the two arms of TasP, where universal testing was done in
both arms and population-level suppression increased simi-
larly in both arms over an average of two-year follow-up.
Annual incidence was not measured. Putting these trial results
together –HIV incidence decreased over a very short time
when universal testing, robust linkage, and ART start were
deployed.
The estimates of the effect of UTT on incidence were likely
underestimated across the four studies for several reasons.
First, in randomized comparisons of HIV incidence within each
study, ART eligibility expanded in control arms early in all stud-
ies. Second, the intervention effect was likely diluted by in-and-
out migrations, which would have less of an effect if UTT were
implemented in broader geographic regions, although mobile
populations face unique challenges for HIV testing and long-
term care [27]. Third, even for interventions with profound
impacts on HIV incidence over the longer term, one expects
only modest reductions during the first three years the inter-
vention is delivered, considering that increasing viral suppres-
sion requires HIV testing, ART start and months to achieve viral
suppression. HPTN 071 modelling work illustrates increasing
gains in incidence reduction over time with UTT [28].
HIV-associated mortality must be assessed by comprehen-
sive vital status assessment and only one trial has released
such information so far. Mortality was reduced by 23% in
the intervention versus control communities in SEARCH. The
mortality difference in SEARCH was most prominent in
men HIV+ at study baseline with CD4+ cells <350/mm3
[29]; a population with identical baseline diagnosis and treat-
ment eligibility in both arms, but who received a differenti-
ated care delivery strategy only in the intervention arm.
Mobilization of men and rapid ART start via multi-disease
community testing of those who were asymptomatic but had
low CD4 and were at high risk for disease progression and
death is one explanation consistent with these data. The
opportunity of finding persons living with HIV with low CD4
before they develop clinical symptoms and appear at health
facilities as “late presenters” is an overlooked benefit of uni-
versal testing coupled with rapid ART start. Indeed, a 23%
reduction in mortality in such a short time period could have
positive profound effects on mortality in the path to HIV
epidemic control.
2.6 | The public health case for UTT
We now have solid evidence that in SSA, UTT is feasible in a
variety of public health–funded settings and can rapidly
achieve high levels of viral suppression and reduce HIV inci-
dence and deaths faster than the status quo. Importantly, all
UTT trials evaluated testing strategies designed to be feasible
for implementation at scale; while some cost effectiveness
analyses are currently underway, those published shows costs
in line with alternative approaches, and support the cost effec-
tiveness of a UTT approach [28,30,31]. In modelled projec-
tions based on HPTN 071, HIV incidence would be reduced
by up to 50% if the intervention were continued to 2030
[28]. The full potential of UTT is likely to be even greater with
widespread implementation (hence blunting of migration
effects) and with the addition of pre-exposure prophylaxis and
other up and coming prevention modalities that also require
HIV testing. Finally, as more and more countries move
towards an integrated universal health approach, a multi-dis-
ease UTT approach could increase efficiencies and enhance
gains for broader health outcomes [32,33]. SEARCH showed
population benefits in hypertension control and reductions in
HIV-associated tuberculosis incidence with a multi-disease
model and reported very modest costs for integration of
hypertension care into HIV clinics [34].
As universal treatment is now the global standard, argu-
ments against UTT are mainly that the upfront cost of pop-
ulation-level universal testing is too high, and that the yield
of testing will be low. The yield of HIV testing will be
indeed higher and testing costs will be lower with targeted
testing approaches (at-risk groups, partner notification) ver-
sus universal testing. However, models for HIV epidemic
control show that limiting HIV testing exclusively to high-
risk groups is neither the fastest nor most effective strat-
egy, particularly in generalized epidemics, because this
approach misses the majority of persons with unknown HIV
status [35]. For example, in Zimbabwe, over 70% of persons
with unknown status are men and women not classified into
“high risk” groups. Moreover the “costs” of testing need to
be considered in the context of the opportunity to offer
multi-disease prevention and treatment services on a path
to universal health coverage.
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3 | CONCLUSIONS
These trials demonstrate that UTT with universal testing,
robust linkage and access to ART care can rapidly achieve
high population-level viral suppression leading to significant
reductions in HIV incidence and mortality, and can do so more
effectively than contemporary approaches in SSA. Universal
testing is not current policy, even in SSA countries with gener-
alized epidemics, and HIV testing remains focused on more
targeted strategies aiming to reach key populations. We pro-
pose that a UTT package tailored to epidemic context be
implemented at a sub-country level in geographic areas where
there is high HIV prevalence and a substantive proportion of
people living with HIV with unsuppressed levels of HIV RNA.
Design and delivery of the UTT package can draw insights
from these UTT studies, and we suggest additional evidence-
based prevention measures should be integrated to further
accelerate the path to ending the HIV epidemic.
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